Janssen Biotech has entered into a definitive agreement to acquire a privately-held biopharmaceutical company focused on the red-hot field of cancer immunology.
Financial terms of the deal for BeneVir BioPharm are being kept confidential.
{iframe}https://www.bizjournals.com/baltimore/news/2018/05/03/janssen-biotech-buying-benvir-biopharm-jnj-oncolog.html{/iframe}